Michael P Combs1, Meng Xia2, David S Wheeler1, Elizabeth A Belloli1, Natalie M Walker1, Russell R Braeuer1, Dennis M Lyu1, Susan Murray2, Vibha N Lama3. 1. Department of Internal Medicine, Division of Pulmonary & Critical Care, University of Michigan, Ann Arbor, Michigan. 2. Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. 3. Department of Internal Medicine, Division of Pulmonary & Critical Care, University of Michigan, Ann Arbor, Michigan. Electronic address: vlama@umich.edu.
Abstract
BACKGROUND: Chronic lung allograft dysfunction (CLAD), the primary cause of poor outcome after lung transplantation, arises from fibrotic remodeling of the allograft and presents as diverse clinical phenotypes with variable courses. Here, we investigate whether bronchoalveolar lavage (BAL) mesenchymal cell activity at CLAD onset can inform regarding disease phenotype, progression, and survival. METHODS: Mesenchymal cell colony-forming units (CFUs) were measured in BAL obtained at CLAD onset (n = 77) and CLAD-free time post-transplant matched controls (n = 77). CFU counts were compared using Wilcoxon's rank-sum test. Cox proportional hazards and restricted means models were utilized to investigate post-CLAD survival. RESULTS: Higher mesenchymal CFU counts were noted in BAL at the time of CLAD onset than in CLAD-free controls. Patients with restrictive allograft syndrome had higher BAL mesenchymal CFU count at CLAD onset than patients with bronchiolitis obliterans syndrome (p = 0.011). Patients with high mesenchymal CFU counts (≥10) at CLAD onset had worse outcomes than those with low (<10) CFU counts, with shorter average survival (2.64 years vs 4.25 years; p = 0.027) and shorter progression-free survival, defined as time to developing either CLAD Stage 3 or death (0.97 years vs 2.70 years; p < 0.001). High CFU count remained predictive of decreased overall survival and progression-free survival after accounting for the CLAD phenotype and other clinical factors in multivariable analysis. CONCLUSIONS: Fulminant fibroproliferation with higher mesenchymal CFU counts in BAL is noted in restrictive allograft syndrome and is independently associated with poor survival after CLAD onset.
BACKGROUND:Chronic lung allograft dysfunction (CLAD), the primary cause of poor outcome after lung transplantation, arises from fibrotic remodeling of the allograft and presents as diverse clinical phenotypes with variable courses. Here, we investigate whether bronchoalveolar lavage (BAL) mesenchymal cell activity at CLAD onset can inform regarding disease phenotype, progression, and survival. METHODS: Mesenchymal cell colony-forming units (CFUs) were measured in BAL obtained at CLAD onset (n = 77) and CLAD-free time post-transplant matched controls (n = 77). CFU counts were compared using Wilcoxon's rank-sum test. Cox proportional hazards and restricted means models were utilized to investigate post-CLAD survival. RESULTS: Higher mesenchymal CFU counts were noted in BAL at the time of CLAD onset than in CLAD-free controls. Patients with restrictive allograft syndrome had higher BAL mesenchymal CFU count at CLAD onset than patients with bronchiolitis obliterans syndrome (p = 0.011). Patients with high mesenchymal CFU counts (≥10) at CLAD onset had worse outcomes than those with low (<10) CFU counts, with shorter average survival (2.64 years vs 4.25 years; p = 0.027) and shorter progression-free survival, defined as time to developing either CLAD Stage 3 or death (0.97 years vs 2.70 years; p < 0.001). High CFU count remained predictive of decreased overall survival and progression-free survival after accounting for the CLAD phenotype and other clinical factors in multivariable analysis. CONCLUSIONS: Fulminant fibroproliferation with higher mesenchymal CFU counts in BAL is noted in restrictive allograft syndrome and is independently associated with poor survival after CLAD onset.
Authors: Takeshi Mimura; Natalie Walker; Yoshiro Aoki; Casey M Manning; Benjamin J Murdock; Jeffery L Myers; Amir Lagstein; John J Osterholzer; Vibha N Lama Journal: Am J Pathol Date: 2015-04-04 Impact factor: 4.307
Authors: Daniel C Chambers; Roger D Yusen; Wida S Cherikh; Samuel B Goldfarb; Anna Y Kucheryavaya; Kiran Khusch; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Joseph W Rossano; Josef Stehlik Journal: J Heart Lung Transplant Date: 2017-07-19 Impact factor: 10.247
Authors: Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Masaaki Sato; Thomas K Waddell; Ute Wagnetz; Heidi C Roberts; David M Hwang; Ayesha Haroon; Dirk Wagnetz; Cecilia Chaparro; Lianne G Singer; Michael A Hutcheon; Shaf Keshavjee Journal: J Heart Lung Transplant Date: 2011-03-17 Impact factor: 10.247
Authors: Stijn E Verleden; Dragoş M Vasilescu; John E McDonough; David Ruttens; Robin Vos; Elly Vandermeulen; Hannelore Bellon; Rachel Geenens; Erik K Verbeken; Johny Verschakelen; Dirk E Van Raemdonck; Wim A Wuyts; Youri Sokolow; Christiane Knoop; Joel D Cooper; James C Hogg; Geert M Verleden; Bart M Vanaudenaerde Journal: Eur Respir J Date: 2015-06-25 Impact factor: 16.671
Authors: Lamis Jarvinen; Linda Badri; Scott Wettlaufer; Takashi Ohtsuka; Theodore J Standiford; Galen B Toews; David J Pinsky; Marc Peters-Golden; Vibha N Lama Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Susan Stewart; Michael C Fishbein; Gregory I Snell; Gerald J Berry; Annette Boehler; Margaret M Burke; Alan Glanville; F Kate Gould; Cynthia Magro; Charles C Marboe; Keith D McNeil; Elaine F Reed; Nancy L Reinsmoen; John P Scott; Sean M Studer; Henry D Tazelaar; John L Wallwork; Glen Westall; Martin R Zamora; Adriana Zeevi; Samuel A Yousem Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: Claus Neurohr; Patrick Huppmann; Benedikt Samweber; Stefan Leuschner; Gregor Zimmermann; Hanno Leuchte; Rainer Baumgartner; Rudolf Hatz; Ludwig Frey; Peter Ueberfuhr; Iris Bittmann; Juergen Behr Journal: J Heart Lung Transplant Date: 2009-03-14 Impact factor: 10.247
Authors: Elizabeth A Belloli; Tian Gu; Yizhuo Wang; Dharshan Vummidi; Dennis M Lyu; Michael P Combs; Aamer Chughtai; Susan Murray; Craig J Galbán; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2021-10-15 Impact factor: 30.528